Left Ventricular Thrombus Management After Acute Myocardial Infarction in Clinical Practice: Results from LEVITATION Survey and Narrative Review
Articolo
Data di Pubblicazione:
2022
Citazione:
Left Ventricular Thrombus Management After Acute Myocardial Infarction in Clinical Practice: Results from LEVITATION Survey and Narrative Review / L.A.F. Di Odoardo, M. Bianco, I.J.N. Gil, I.G. Motolese, A. Chinaglia, M. Vicenzi, S. Carugo, G.G. Stefanini, E. Cerrato. - In: CARDIOVASCULAR DRUGS AND THERAPY. - ISSN 0920-3206. - (2022), pp. 1-10. [Epub ahead of print] [10.1007/s10557-022-07417-w]
Abstract:
Purpose: Left ventricular thrombus (LVT) after ST-elevation myocardial infarction still presents diagnostic and therapeutic challenges. The LEVITATION survey was designed to take a picture of LVT management in current clinical practice.Methods: The survey covered diagnostic, therapeutic, and prophylactic issues and was completed by 104 European cardiac centers. Most of them (59%) were university or tertiary centers.Results: The survey showed anterior apical a-/dyskinesia, large MI, spontaneous echo-contrast, late presentation with delayed PCI, and TIMI flow 0-1 as the most important perceived risk factors for LVT formation. Serial ultrasound imaging is the most used tool to diagnose LVT (88% of the centers), with contrast-enhanced ultrasound and cardiac MR performed in case of poor apex visualization or spontaneous echo-contrast. One third (34%) of the centers uses prophylactic anticoagulation to prevent LVT formation. In the presence of LVT, low molecular weight heparin is the most used in-hospital therapy. At discharge, vitamin K antagonist and direct oral anticoagulants are used in 67 and 32% of the cases, respectively. Triple antithrombotic therapy with aspirin plus clopidogrel and VKA is the most used strategy at discharge (55%), whereas a single antiplatelet therapy is preferred only in the case of moderate-to-high risk of bleeding. To assess LVT total regression, half of the centers use contrast-enhanced ultrasound and/or cardiac-MR. The duration of anticoagulation is usually 3-6 months (55%), with long-term prolongation in case of LVT persistence or recurrence.Conclusion: The survey has depicted for the first time the current real-world management of this neglected topic and has highlighted several grey zones that are still present and not supported by evidence.
Tipologia IRIS:
01 - Articolo su periodico
Keywords:
Acute cardiac care; Antithrombotic therapy; Direct oral anticoagulant (DOAC); Left ventricular thrombus; ST-elevation myocardial infarction (STEMI); Survey
Elenco autori:
L.A.F. Di Odoardo, M. Bianco, I.J.N. Gil, I.G. Motolese, A. Chinaglia, M. Vicenzi, S. Carugo, G.G. Stefanini, E. Cerrato
Link alla scheda completa: